Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00003713 | Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors | PHASE1 | COMPLETED | 35 | — | — | Aug 1, 1997 | - | Aug 29, 2018 | 3 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| intoplicine | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically proven solid tumor refractory to conventional cytotoxic anticancer therapy or for which no curative therapy exists Measurable or evaluable disease No active, progressive brain metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance s...